Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KRAS | P01116 | 3/20 | 0.55 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.35 |
| ▸ | FNTA | P49354 | 3/20 | 0.34 |
| ▸ | FNTB | P49356 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | STS | P08842 | 3/20 | 0.33 |
| ▸ | IL1B | P01584 | 2/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.33 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16122675 | 0.91 | KRAS (0.44) | KRASUSP30STSEPHX2 | |
| SCHEMBL30642306 | 0.89 | KRAS (0.68) | KRASUSP30FNTAFNTBSTS | |
| SCHEMBL16129263 | 0.89 | KRAS (0.68) | KRASUSP30FNTAFNTBSTS | |
| SCHEMBL16100135 | 0.85 | KRAS (0.77) | KRAS | |
| SCHEMBL31672360 | 0.85 | KRAS (0.77) | KRAS | |
| SCHEMBL21458760 | 0.83 | KRAS (0.74) | KRASUSP30FNTAFNTBSTS | |
| SCHEMBL16102313 | 0.81 | KRAS (0.46) | KRASSTS | |
| SCHEMBL30642275 | 0.80 | KRAS (0.48) | KRASSTSMEN1KMT2A | |
| SCHEMBL16098954 | 0.80 | KRAS (0.48) | KRASSTSMEN1KMT2A | |
| SCHEMBL16122668 | 0.78 | KRAS (0.60) | KRAS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10273207-B2 | Covalent inhibitors of kras G12C | ARAXES PHARMA LLC (US) | 2019-04-30 | — | — | US | disclosed |
| US-20180162812-A1 | COVALENT INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2018-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180162812-A1 | COVALENT INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | KRAS 1/4885USP30 340/4885FNTA 442/4885 |
| US-10273207-B2 | Covalent inhibitors of kras G12C | KRAS, NRAS, HRAS | KRAS 1/4885USP30 340/4885FNTA 442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.